| Vol. 16.37 – 22 September, 2021 |
| |
|
|
| The authors described CRISPRpath, a scalable screening strategy for parallelly characterizing cis-regulatory elements of genes linked to the same biological pathway and converging phenotypes. [Science Advances] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators used iPSC technology to obtain hippocampal neurons to investigate the neuropathology of IQSEC2-mediated disease. The neurons were characterized at three-time points during differentiation to assess developmental progression. [Molecular Psychiatry] |
|
|
|
| Researchers attempted to model human early embryo development with expanded PSCs (EPSCs) in 3-dimensions. They defined a protocol that allowed them to generate self-organizing cystic structures from human EPSCs that displayed some hallmarks of human early embryogenesis. [Nature Communications] |
|
|
|
| Using multi-omics data, scientists demonstrated the existence of two retinoblastoma subtypes. They expressed markers of less differentiated cone together with neuronal/ganglion cell markers with marked inter- and intra-tumor heterogeneity. [Nature Communications] |
|
|
|
| Spinocerebellar ataxia type 3 (SCA3)-iPSCs could be corrected by the replacement of the abnormal CAG expansions with normal repeats using CRISPR/Cas9-mediated homologous recombination strategy. Corrected SCA3-iPSCs retained pluripotent and normal karyotype, which could be differentiated into a neural stem cell and neuronal cells. [Translational Psychiatry] |
|
|
|
| The authors presented a transgenic, TAR DNA-binding protein-43 (TDP-43)-A315T, mouse model expressing an Amyotrophic Lateral Sclerosis (ALS) phenotype and demonstrated the presence of ubiquitinated cytoplasmic TDP-43 aggregates with > 80% cell death by 28 days post differentiation in vitro. [Scientific Reports] |
|
|
|
| To explore the developmental toxicity of 2,2′,4,4′-Tetrabromodiphenyl ether (BDE47), mouse ESCs, which are ideal models for testing the developmental toxicity of environmental contaminants in vitro, were exposed to BDE47 for 24 hours or 48 hours in this study. [Reproductive Toxicology] |
|
|
|
| Researchers investigated the chemical sensitivity of the ESTc carried out under 20% O2, using ESCs cultured under either 20% O2 or 5% O2. ESC viability was more sensitive to valproic acid but less sensitive to flusilazole when cultured under 5% versus 20% O2. [Toxicology in Vitro] |
|
|
|
| The authors investigated the contribution of the Bax, Sirt-1, TGF-β, and MALAT genes and/or their protein expression to the pathogenesis of submandibular carcinogenesis before and after iPSCs treatment. [Molecular and Cellular Biochemistry] |
|
|
|
| Researchers developed erythroblasts with custom phenotypes using CRISPR/Cas9 gene-editing of a human iPSC parent line for the blood group system genes: RHAG, GYPB and XK. [STAR Protocols] |
|
|
|
| Investigators provided a detailed protocol for the transfection of mouse ESCs and mouse-iPSCs with a Zscan5b constitutive expression plasmid, using the piggyBac transposon gene expression vector system. [STAR Protocols] |
|
|
|
|
| The authors discuss how deficits in neurodevelopmental processes may lead to abnormal brain connectivity and how iPSC-based models can be used to identify abnormal connections and to gain insights into underlying cellular and molecular mechanisms to develop novel therapeutics. [Molecular Psychiatry] |
|
|
|
| Scientists review the role of bromodomain protein 4 in complex gene regulatory networks during three specific states of stem cell transitions: cell differentiation, cell reprogramming, and transdifferentiation. [Stem Cells] |
|
|
|
|
| Dr. Frank Barry has been selected as the new director of the C. Wayne McIlwraith Translational Medicine Institute at Colorado State University. Barry’s research and interests include stem cell biology and the development of cell-based repair strategies for osteoarthritis. [Colorado State University] |
|
|
|
| The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million. [Stanford Medicine] |
|
|
|
|
| October 19 – 22, 2021 Virtual |
|
|
|
|
|
| Wellcome Sanger Institute – Cambridge, England, United Kingdom |
|
|
|
| King Abdullah University of Science and Technology – Thuwal, Saudi Arabia |
|
|
|
| MaxWell Biosystems – Zurich, Switzerland |
|
|
|
| NHS Blood and Transplant – Oxford, England, United Kingdom |
|
|
|
| University of Southern California – Los Angeles, California, United States |
|
|
|
|